Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Dai-chang Yang"'
Publikováno v:
Drug Metabolism and Disposition. 30:1013-1021
Valdecoxib is a potent and specific inhibitor of cyclooxygenase-2, which is used for the treatment of rheumatoid arthritis, osteoarthritis, and the dysmenorrhea pain. Eight male human subjects each received a single 50-mg oral dose of [(14)C]valdecox
Autor:
Yue-Fen Wang, Dai-chang Yang, Ji Y. Zhang, Jinhua Yuan, Susan K. Paulson, Caroline Dudkowski, Ming Chang, Alan P. Breau
Publikováno v:
Journal of Mass Spectrometry. 35:1259-1270
The metabolism of the anti-inflammatory drug Celecoxib in rabbits was characterized using liquid chromatography (LC)/tandem mass spectrometry (MS/MS) with precursor ion and constant neutral loss scans followed by product ion scans. After separation b
Autor:
Dai-Chang Yang, G. W. Gullikson, Daniel L. Flynn, Daniel P. Becker, Clara I. Villamil, Roger Nosal, Chafiq Moummi
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 7:2149-2154
A series of meso-amino(methyl)azanoradamantane benzamides has been prepared and evaluated for 5-HT4 agonism activity in the rat tunica muscularis mucosae (TMM) assay. Compound 8i is the most potent 5-HT4 agonist in the series, with an EC50 of 217 nM.
Autor:
Dai-Chang Yang, Roger Nosal, Daniel L. Flynn, Clara I. Villamil, Chafiq Moummi, G. W. Gullikson, Daniel P. Becker
Publikováno v:
ChemInform. 29
A series of meso-amino(methyl)azanoradamantane benzamides has been prepared and evaluated for 5-HT4 agonism activity in the rat tunica muscularis mucosae (TMM) assay. Compound 8i is the most potent 5-HT4 agonist in the series, with an EC50 of 217 nM.
Autor:
Chafiq Moummi, Dai-Chang Yang, Daniel L. Flynn, Roger Nosal, Daniel P. Becker, G. W. Gullikson, Dale P. Spangler
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 2:1613-1618
New aza(nor)adamantanes 1A , 1B , and 1C are described which exhibit properties of both 5-HT4 agonism and 5-HT3 antagonism. In particular, compound 1C [SC-52491], an azanoradamantane, exhibits an EC50 of 51 nM in a functional model of 5-HT4 agonism a
Autor:
Daniel L. Flynn, Chafiq Moummi, Dai-Chang Yang, Daniel P. Becker, G. W. Gullikson, Clara I. Villamil
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 2:1251-1256
A new series of cholecystokinin (CCK) antagonists are described which utilizes a new 1,3,4-trisubstituted pyrrolidinone as a scaffold for appending specific amino acid R group mimics (Figure 1). Compound 1A and 1E (SC-50998) exhibit potent nanomolar
Publikováno v:
European Journal of Pharmacology. 216:47-52
Changes in mechanical events and intracellular levels of cAMP induced by the activation of the 5-HT4 receptor were investigated in the rat esophagus tunica muscularis mucosae preparation. Serotonin (5-HT) and 5 methoxytryptamine (5-MOT; 5-HT4 agonist
Autor:
Maida A. Virina, Dai-Chang Yang, Bela Goldstin, Alan E. Moormann, Daniel L. Flynn, R F Loeffler, G. W. Gullikson
Publikováno v:
Drug Development Research. 26:405-417
Zacopride is an antiemetic agent whose (S) and (R) stereoisomers demonstrate differential pharmacology at 5-HT3 receptors, emphasizing the importance of pharmacologic profiling of each enantiomer of a racemic drug mixture. Characterization of the gas
Publikováno v:
Journal of pharmacokinetics and biopharmaceutics. 23(1)
Certain compounds such as SC-52151 have extensive nonspecific adsorption to the ultrafiltration devices or to dialysis membranes and therefore can not be measured by the conventional ultrafiltration or equilibrium dialysis methods. A new method based
Autor:
Mary Alice Stetler-Stevenson, Linda McCartney, Darryl R. Peterson, George Flouret, Dai Chang Yang, Andrew Lipkowski
Publikováno v:
Journal of Medicinal Chemistry. 24:688-692
Metabolic breakdown of the luteinizing hormone-releasing hormone (LH-RH) could lead to the following fragments containing pyroglutamic acid: pyroglutamic acid (1), pGlu-His (2), pGLu-His-Trp (3), pGlu-His-Trp-Ser (4), etc., and finally pGlu-His-Trp-S